Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What's the recommended time to take lipitor around yogurt?Does olive oil affect lipitor's heart health benefits?How does fatty food impact lipitor's efficacy?How does opioid use affect lipitor's efficacy?How does lyrica's mechanism lead to muscle weakness?
See the DrugPatentWatch profile for Edoxaban
Edoxaban Patent: Exclusivity and Competition Edoxaban, a direct oral anticoagulant, is marketed by Daiichi Sankyo under the brand name Lixiana among others [1]. Its patent life is a significant concern for companies like AstraZeneca and Pfizer, which are working to develop biosimilars and generic alternatives [2]. Why are companies challenging this patent? Pharmaceutical companies are challenging the patent because edoxaban's exclusivity period ends on April 20, 2027, in the US, where it is approved for the treatment and prevention of deep vein thrombosis and pulmonary embolism [3]. The exclusivity period is the time during which the generic manufacturer cannot market the generic version of the drug. What happens if competitors bring a generic version before patent expiry? The introduction of a generic version before patent expiry can significantly reduce the sales of the brand-name drug, affecting revenue for Daiichi Sankyo [4]. However, this doesn't necessarily stop the development of biosimilars, which can enter the market earlier if they demonstrate sufficient efficacy and safety. When does exclusivity expire? According to the US FDA, exclusivity for edoxaban expires on April 20, 2027 [5]. By that date, generic manufacturers can enter the US market with their versions of the drug. How does this impact patients and healthcare providers? The increased availability of generic or biosimilar alternatives can provide patients with more affordable treatment options, improving access to anticoagulant therapy. However, patients and healthcare providers need to discuss the potential benefits and risks of any treatment option with their healthcare provider. Sources: [1] https://www.drugpatentwatch.com/drug/edoxaban [2] https://www.risk-benefit.com/edoxaban-daiichi-sankyo-astaz-lpx [3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205549Orig1s022lbl.pdf [4] https://www.drugpatentwatch.com/drug/edoxaban/generic-versions [5] https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (FDA approved drugs) [6] Drug Patent Watch: edoxaban.